salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing
TRANSCRIPT
![Page 1: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/1.jpg)
Arzu TOPELİ İSKİT
Hacettepe University Faculty of Medicine, Director of MICU
Council Memeber of WFSICCM
What is new after sepsis guideline?
![Page 2: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/2.jpg)
Presentation Plan
• What is new in sepsis epidemiology?
• What is new in sepsis diagnosis?
• What is new in sepsis management?
![Page 3: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/3.jpg)
What is new in sepsis epidemiology?
![Page 4: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/4.jpg)
World Sepsis Declaration
• Sepsis is frequent but less known
in the world.
• Sepsis affects 20-30 million people
each year.
▫ 300->1000 / 100.000 people
• In the last decade incidence
increased bu 13%/yr.
• One person dies every 1-2 sec due
to sepsis.
![Page 5: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/5.jpg)
![Page 6: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/6.jpg)
Sepsis Mandates: Improving Inpatient Care While Advancing Quality Improvement
• Mortality rate in acute myocadial infarction,
congestive heart failure and pneumonia
<10%.
• ½ deaths in the hospital are due to sepsis.
Cooke & Iwashyna. JAMA 2014;312(14):1397.
Sepsis is a public health problem !
![Page 7: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/7.jpg)
Crit Care Med 2014; Sep.
![Page 8: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/8.jpg)
Ani, et al. Crit Care Med 2014; Sep.
![Page 9: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/9.jpg)
![Page 10: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/10.jpg)
![Page 11: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/11.jpg)
What is new in sepsis diagnosis?
![Page 12: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/12.jpg)
Sepsis is a systemic inflammatory response to infection.
ACCP/SCCM 1992
Septic
shock +MO
F
SEPSIS
![Page 13: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/13.jpg)
ACCP/SCCM 1992
![Page 14: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/14.jpg)
2001 International Sepsis Conference
![Page 15: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/15.jpg)
Zhao H, et al. Crit Care Med 2012;40:1700
![Page 16: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/16.jpg)
Severe Sepsis
Refractory hypotension Septic shock
![Page 17: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/17.jpg)
Sensitivity
0.77
Specificity
0.79
AUC 0.85
![Page 18: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/18.jpg)
• Sepsis is the host’s deleterious and non-resolving
inflammatory response
to infection leading to organ dysfunction
▫ Cardiovascular
▫ Respiratory
▫ Renal
▫ Neurologic
▫ Hepatic
▫ Coagulation
▫ Gut
▫ Endocrine
«… we believe evidence of organ
dysfunction should be included in the
criteria for sepsis—ie, sepsis should be
defined as a systemic response to infection
with the presence of some degree of organ
dysfunction…»
![Page 19: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/19.jpg)
What is new in sepsis management?
![Page 20: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/20.jpg)
Sepsis Campaign: 2002
ISF(International Sepsis Forum)
IHI(Institute for
Healthcare
Improvement)
SCCM
ESICM
GUIDELINES
BUNDLES
Aim: Decrease in mortality RR by
25% in 5 yrs
![Page 21: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/21.jpg)
Sepsis Campaign/Guidelines
2002 Barcelona
Declaration
2004Guideline
2008Guideline
2012 Guideline
AwarenessEarly diagnosis
Rapid appropriate treatmentEducation
Intervention beyond ICULocal and global guidelines
![Page 22: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/22.jpg)
![Page 23: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/23.jpg)
Similarities in 2004 – 2008 – 2012 Guidelines• EGDT – 6 hrs
• Antibiotics – 1 hr
• Infection management
• Prophylaxies and general management
• Use of blood product use
• Sedation management
• Mechanical ventilation management
• Renal replacement therapies
• …
![Page 24: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/24.jpg)
Main Points Emphasized in the Last Guideline• Protocol based resuscitation targeting specific physiologic
targets
• Antibiotic treatment in 1 hr after clinical diagnosis
• Preferential use of crystalloids in volume resuscitation
• Preferential use of nor-epinephrine as vasopressor
• Not using corticosteroids routinely if shock state is
controlled with fluids and vasopressors
• Use of lactate and clearence for monitorization of tissue
hypoperfusion
![Page 25: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/25.jpg)
![Page 26: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/26.jpg)
Compliance to Bundles
•Around 20% (25 000 pt)
Levy, et al. Lancet Infect Dis 2012;12:919Levy, et al. Intensive Care Med 2014; Oct.
![Page 27: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/27.jpg)
Recombinant human activated protein C for adults with septic shock: a randomized controlled trialAnnane D, et al. APROCCHSS Trial Investigators.
•No difference between placebo and
APC in mortality
Am J Respir Crit Care Med 2013 May 15;187:1091
![Page 28: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/28.jpg)
Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. Annane D, et al. JAMA 2013 Nov 6;310:1809
•Similar 28 d mortality; lower 90 d
mortality in the colloid group
•More ventilator and vasopressor free
days in the colloid group
![Page 29: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/29.jpg)
![Page 30: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/30.jpg)
•Protocol driven EGDT
▫Protocol of the first EGDT trial …
•Protocol driven standard therapy
▫Reaching goals in 6 hr: peripheral
catheter, hourly monitorization, SBP,
shock index
•Usual treatment
![Page 31: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/31.jpg)
![Page 32: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/32.jpg)
80-85 mmHg-
65-70 mmHg
![Page 33: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/33.jpg)
•EGDT vs standard treatment
•More fluid, vasopressor, dobutamin
and blood product use in EGDT group
•No difference in mortality
![Page 34: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/34.jpg)
• 80 mg Enteral Simvastatin 28 d vs placebo
• Similar mortality and ventilator free days
N Engl J Med 2014; 371:1695
![Page 35: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/35.jpg)
Doig, et al. ANZICS CTG. JAMA 2013;309:2130
![Page 36: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/36.jpg)
• Early EN vs PN
• Similar calories
• Less vomitting and hypoglycemia in PN
• Similar infection rates and mortality
![Page 37: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/37.jpg)
![Page 38: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/38.jpg)
For 96 hrs heart rate 80-94 bpm
![Page 39: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/39.jpg)
Less fluid and norepi use and SVI in esmolol group
![Page 40: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/40.jpg)
![Page 41: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/41.jpg)
New Agents• A randomized, double-blind, placebo-controlled, Phase 2b study to
evaluate the safety and efficacy of recombinant human soluble
thrombomodulin, ART-123, in patients with sepsis and suspected
disseminated intravascular coagulation. Vincent JL, et al. Crit Care
Med 2013 Sep;41:2069
▫ Safe
• A phase 2 randomized, double-blind, placebo-controlled study of
the safety and efficacy of talactoferrin in patients with severe
sepsis. Guntupalli K, et al. TLF LF-0801 Investigator Group. Crit
Care Med 2013 Mar;41:706
▫ Decrease in 28 d and 6 mo mortality by use of Talactoferrin which is a
recombinant human laktoferrin
![Page 42: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/42.jpg)
Ungoing Studies• A protocol for a multicentre randomised controlled trial of continuous beta-
lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. ANZICS CTG
• The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. ANZICS CTG
• Enteral vs. intravenous ICU sedation management: study protocol for a randomized controlled trial. SedaEN investigators
• Medical education for sepsis source control and antibiotics: The MEDUSA study
• HEROICS study
• Sepsis pathophysiological & organisational timing: The SPOT(Light) study
• Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis (SISPCT)
![Page 43: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/43.jpg)
![Page 44: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/44.jpg)
![Page 45: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/45.jpg)
>100 Phase III Studies with (-) Results• Corticosteroids
• Agents targeting LPS or TLR-
4
• Agents targeting TNF
• Agents targeting IL-1
• Agents targeting PAF
• Agents targeting coagulation
cascade
• Agents up-regulating immune
function
• Others
▫ NOS inhibitors
▫ Ibuprofen
▫ Pentoxifylline
▫ NAC
• …
![Page 46: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/46.jpg)
SIRS
CARS
Hotchkiss, et al. Lancet Infect Dis 2013;13:260.
![Page 47: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/47.jpg)
In Summary …• Sepsis is a public health problem with increasing incidence.
• More than 10 yrs ago sepsis campaign was established to
increase awareness and improve survival.
• 3 guidelines was published the last of which in February
2013.
• Although there is some decrease in mortality, compliance to
guidelines and bundles is still low.
• An advance in diagnosis and treatment has not been
observed so far.
![Page 48: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/48.jpg)
![Page 49: Salon a 14 kasim 09.00 10.15 arzu topeli̇ i̇ski̇t-ing](https://reader035.vdocuments.mx/reader035/viewer/2022062515/55c328a1bb61eb3c348b47c7/html5/thumbnails/49.jpg)
Thank you …[email protected]